Items Tagged ‘ESMO’

October 26th, 2016

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer

By

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the […]

View full entry

Tags: 2016, Breast Cancer, ESMO, Femera, hormone-receptor positive, HR+ metastatic, letrozole, Metastatic Breast Cancer, MONALEESA-2 clinical, News, ribociclib LEE011


October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


October 24th, 2016

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients

By

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are at high risk of recurrence following complete surgical resection. In the study, Yervoy compared with placebo significantly improved overall survival (OS) with five-year OS rates at 65.4% […]

View full entry

Tags: 2016, advanced melanoma, ESMO, high-risk, ipilimumab, Melanoma, News, overall survival, stage III, Stage III Melanoma, Yervoy


October 20th, 2016

Tesaro Provides Real Benefit to Ovarian Cancer Patients

By

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase (PARP) inhibitor with chemotherapy. Tesaro improved cancer-free survival by 73% in patients with a BRCA mutation and by 55% in those without such mutations. The new data were presented at the […]

View full entry

Tags: 2016, BRCA mutation, ESMO, News, niraparib, Ovarian Cancer, parp, poly(ADP)-ribose polymerase, recurrent, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer, Tesaro


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab